Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 23.4% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hypertonic sodium chloride solution increases plasma osmolality, drawing water from intracellular to extracellular space, expanding intravascular volume, and promoting diuresis. It also provides sodium and chloride ions for electrolyte replenishment.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Severe symptomatic hyponatremia (e.g., serum sodium <120 m Eq/L with neurological symptoms),Intracranial hypertension (osmotic diuresis to reduce cerebral edema)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Severe hyponatremia: 100-150 m L of 23.4% sodium chloride (27-40 g Na Cl) IV over 1-2 hours via central line; maximum rate 1-2 m L/min. Repeat dose based on serum sodium levels. Not for direct IV push; must be diluted or used via central line.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable as sodium chloride is an electrolyte; distribution and elimination follow body sodium homeostasis, with renal regulation having a half-life of hours to days depending on volume status.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Not metabolized; sodium and chloride ions are excreted primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >95% as sodium and chloride ions; negligible biliary/fecal.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
0%; not bound to plasma proteins.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
0.6–0.7 L/kg; distributes into extracellular fluid.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: 100% (passive absorption); IV: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No standard GFR-based dose adjustment; use caution in renal impairment due to risk of fluid overload and hypernatremia. Monitor serum electrolytes and volume status closely.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific Child-Pugh based adjustment; use with caution in cirrhosis with ascites due to fluid overload risk. Monitor sodium and volume.
No dosage adjustment required for hepatic impairment.
Severe symptomatic hyponatremia: 0.5-1 m L/kg of 23.4% sodium chloride (115-230 mg Na Cl/kg) IV over 1-2 hours; maximum 100 m L. Administer via central line. Repeat based on serum sodium correction.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use lowest effective dose; monitor for fluid overload, hypernatremia, and cardiac decompensation. Dose same as adult but adjust for renal function and comorbidities. Consider slower infusion rate.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Not FDA-approved for injection; extravasation causes severe tissue necrosis. Use extreme caution to avoid extravasation during administration.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of central pontine myelinolysis (osmotic demyelination) with rapid correction of hyponatremia,Extravasation hazard leading to tissue necrosis,May cause fluid overload, hypernatremia, and hyperchloremic metabolic acidosis,Use with caution in patients with heart failure, renal impairment, or edema
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypernatremia,Fluid overload states (e.g., pulmonary edema),Known hypersensitivity to sodium chloride
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Dietary restrictions typically involve avoiding high-sodium foods if concurrent salt supplementation is not needed. Patients with hyponatremia may need controlled sodium intake; follow specific dietary guidelines from your provider. Avoid excessive fluid intake as it may dilute sodium levels.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
No known teratogenic risk; sodium chloride is a normal blood constituent. However, hypernatremia from high doses may cause fetal dehydration. First trimester: no fetal risk. Second/third trimesters: monitor maternal serum sodium to avoid hypernatremia, which can cause fetal osmotic shifts.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Compatible with breastfeeding. Sodium chloride is normally present in breast milk; M/P ratio approximately 1.0. No adverse effects expected with usual doses.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No specific dose adjustment required. However, physiologic hypervolemia of pregnancy may necessitate careful monitoring to avoid fluid overload. Standard dosing based on individual electrolyte deficits and clinical status.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
23.4% sodium chloride is a hypertonic solution for severe hyponatremia or cerebral edema; administer via central line due to high osmolarity (8000 m Osm/L) to avoid phlebitis. Monitor serum sodium closely — correct at 4-6 m Eq/L over 24 hours to prevent osmotic demyelination. Use with extreme caution in heart failure, renal impairment, or hypovolemia. Do not mix with medications.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is a concentrated salt solution given through a large vein to increase sodium levels in your blood.,You will need frequent blood tests to monitor your sodium and other electrolyte levels.,You may experience headache, nausea, or swelling at the injection site; report these to your healthcare provider immediately.,Notify your doctor if you have a history of heart failure, kidney disease, or if you are on a low-salt diet.,Avoid drinking excessive amounts of water during treatment unless directed by your doctor.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 23.4% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 23.4% is a Electrolyte that works by Hypertonic sodium chloride solution increases plasma osmolality, drawing water from intracellular to extracellular space, expanding intravascular volume, and promoting diuresis. It also provides sodium and chloride ions for electrolyte replenishment.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 23.4% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 23.4% is: Severe hyponatremia: 100-150 m L of 23.4% sodium chloride (27-40 g Na Cl) IV over 1-2 hours via central line; maximum rate 1-2 m L/min. Repeat dose based on serum sodium levels. Not for direct IV push; must be diluted or used via central line.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 23.4% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 23.4% is classified as Category A/B. No known teratogenic risk; sodium chloride is a normal blood constituent. However, hypernatremia from high doses may cause fetal dehydration. First trimester: no fetal risk. Second. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.